| Experimental Information |
| |
| Enzymatic Activity |
| Molecule Id | EGIN0001225 |
| PMID | 16078851 |
| Assay Used | Enzymatic assay and Cellular assay |
| Experimently Validated | Yes |
| EGFR (IC50) | 0.07 ± 0.03 nM |
| HER2 (IC50) | 25-50 nM |
| HER4 (IC50) | - |
| Mutant L858R (IC50) | - |
| Mutant T790M (IC50) | - |
| Double Mutant (IC50) | - |
| Average ERBB2 and ERBB1 (IC50) | - |
| Inhibition EGFR (%) | - |
| Inhibitory Concentration | - |
| Inhibition HER2 (%) | - |
| Inhibitory Concentration | - |
| Ki (EGFR) | - |
| Ki (HER2) | - |
| Ki (HER4) | - |
| Kd (EGFR) | - |
| Kd (L858R) | - |
| Kd (T790M) | - |
| Kd (L858R/T790M) | - |
| Kd (Other mutation) | - |
| Note | The paper describes the High-Affinity Epidermal Growth Factor Receptor (EGFR) Irreversible Inhibitors with Diminished Chemical Reactivities as Positron Emission Tomography (PET)-Imaging Agent Candidates of EGFR Overexpressing Tumors. |
| Extra | 5-15nM(DHER14-EGFR) |
| |
